Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer

BackgroundAlthough C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second mutati...

Full description

Bibliographic Details
Published in:Frontiers in Oncology
Main Authors: Jiangping Yang, Ping Zhou, Min Yu, Yan Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Subjects:
MET amplification
ROS1
crizotinib
resistance
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.645224/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.645224/full

Similar Items